

This communication should be viewed by:

Primary Care Providers
Behavioral Health Providers
Clinical staff

Pharmaceutical Policy Updates Effective October 1, 2025

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at mvphealthcare.com and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective October 1, 2025, and will be available for viewing on or before September 1, 2025. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Agents for female sexual dysfunction	No Changes
Amtagvi	No Changes
Amtagvi Part B	Updated
Arimoclomol	New
Asfotase alfa	New
CAR T-Cell Therapy	Updated
Daybue	No Changes
Duchenne Muscular Dystrophy	No Changes
GABA Receptor Modulators	Updated
Gabapentin ER	Updated
Ganaxolone	No Changes
Immunoglobulin Therapy	No Changes
Immunoglobulin Therapy Part B	Updated
Lenmeldy	No Changes
Lenmeldy Part B	Updated
Medicare Part B Drug Therapy	No Changes
Medicare Part B vs. Part D Determination	Updated
Monoclonal Antibodies for Alzheimer's Disease	Updated
Monoclonal Antibodies for Alzheimer's Disease- Part B	Updated
Movement Disorders	Updated
Effective August 1, 2025	

Multiple Sclerosis Agents	Updated
Multiple Sclerosis Agents Part B	Updated
Nuedexta	No Changes
Omidubicel	No Changes
Omidubicel Part B	No Changes
Oral Allergen Immunotherapy Medications	Updated
Ozanimod (Zeposia)	Updated
Palforzia	No Changes
Prostate Cancer	Archive
Radicava	No Changes
Radicava Part B	Updated
Palivizumab (formerly Respiratory Syncytial Virus/Synagis)	Updated
Revakinagene Taroretcel	New
Archive Effective January 1, 2026	
Select Hypnotics	Archive
Select Oral Antipsychotics	Archive
Effective September 1, 2025	
Eculizumab (formerly Soliris)	Updated
Spinal Muscular Atrophy	No Changes
Tecelra	No Changes
Tecelra-Part B	No Changes
Tofersen	No Changes
Ravulizumab (formerly Ultomiris)	Updated
Zoladex-Medicaid	No Changes